In elderly subjects with type 1 diabetes mellitus, onset of appearance was twice as fast and early insulin exposure and early glucose-lowering effect were up to twofold greater for faster-acting insulin aspart (faster aspart) than for insulin aspart.

While the total exposure and maximum concentration of faster aspart were ~30% greater in elderly than in younger adults, there were no age group differences in the total or maximum glucose-lowering effect of faster aspart.

The ultra-fast pharmacokinetic and pharmacodynamic properties of faster aspart observed in younger adults are preserved in the elderly, suggesting that faster aspart also has the potential to improve postprandial glucose control over current rapid-acting insulin analogues in elderly patients with diabetes.